FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947745790> ?p ?o ?g. }

• W2947745790 endingPage "e15629" @default.
• W2947745790 startingPage "e15629" @default.
• W2947745790 abstract "e15629 Background: Lenvatinib (LEN) has been approved as a single agent for patients with unresectable hepatocellular carcinoma (u-HCC) since Mar 2018 in Japan. We conducted a nationwide multicenter study and especially focused on the efficacy and safety in the patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial). Methods: A total of 202 patients received LEN from March 2018 at 21 sites in Japan was registered. Tumour assessments in accordance with modified RECIST were done using dynamic CT or MRI within 4-8 weeks and every 6-8 weeks thereafter. Adverse events (AEs) were graded according to the CTCAE ver4.0. Results: In this study, 128 of 202 (63%) patients did not meet the inclusion criteria of the REFLECT trial. For the reasons, 69 patients received TKI therapy before LEN, 37 patients were Child-Pugh B, 6 patients showed main portal vein invasion,13 patients had HCC which occupied ≥ 50% of liver, and 22 patients were with lower platelet ( < 75 × 10⁹ per L) . Median observation time was 4.1 months in all patients, 22 patients died, and median overall survival (OS) was not reached. As the 2nd-line therapy (after sorafenib), 45 patients received LEN and 24 patients did as the 3rd-line (after regorafenib). The OS between TKI naïve and experienced patients was not significantly different, even though baseline albumin level and ALBI score were significantly lower in TKI experienced patients than TKI naïve (p = 0.001 and 0.005). Objective response rate (ORR) and disease control rate (DCR) of TKI naïve patients were 37% and 84%, while those of TKI experienced were 27% and 76%. Child-Pugh B patients (n = 36) had significantly shorter OS than Child-Pugh A (p = 0.01) and median OS in Child-Pugh B patients was 6.1 months. Drug discontinuation due to AEs and elevated aspartate aminotransferase were significantly higher in Child-Pugh B patients (p = 0.005 and 0.001). The OS, treatment duration and drug discontinuation were not significantly different between patients with or without lower platelets. ORR and DCR in patients with lower platelets (n = 22) were 18% and 63%. Conclusions: The response rate of LEN in patients who experienced TKI therapies was similar to that in TKI naïve patients. The median OS in Child-Pugh B patients was 6.1 months and elevated aspartate aminotransferase during LEN was frequently reported in such patients. The OS and treatment duration were not significantly different between patients with or without lower platelets at the cut off of < 75 × 10⁹ per L." @default.
• W2947745790 created "2019-06-07" @default.
• W2947745790 creator A5002013051 @default.
• W2947745790 creator A5005043146 @default.
• W2947745790 creator A5006135689 @default.
• W2947745790 creator A5010404968 @default.
• W2947745790 creator A5018535039 @default.
• W2947745790 creator A5020294749 @default.
• W2947745790 creator A5021816409 @default.
• W2947745790 creator A5023172730 @default.
• W2947745790 creator A5023237476 @default.
• W2947745790 creator A5026178160 @default.
• W2947745790 creator A5035601931 @default.
• W2947745790 creator A5044297659 @default.
• W2947745790 creator A5046992544 @default.
• W2947745790 creator A5062645991 @default.
• W2947745790 creator A5066924600 @default.
• W2947745790 creator A5077526239 @default.
• W2947745790 creator A5079893085 @default.
• W2947745790 creator A5080250007 @default.
• W2947745790 creator A5084452918 @default.
• W2947745790 creator A5085351803 @default.
• W2947745790 date "2019-05-20" @default.
• W2947745790 modified "2023-09-26" @default.
• W2947745790 title "The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) in real-world practice in Japan: A nationwide multicenter study in Japan." @default.
• W2947745790 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e15629" @default.
• W2947745790 hasPublicationYear "2019" @default.
• W2947745790 type Work @default.
• W2947745790 sameAs 2947745790 @default.
• W2947745790 citedByCount "2" @default.
• W2947745790 countsByYear W29477457902022 @default.
• W2947745790 countsByYear W29477457902023 @default.
• W2947745790 crossrefType "journal-article" @default.
• W2947745790 hasAuthorship W2947745790A5002013051 @default.
• W2947745790 hasAuthorship W2947745790A5005043146 @default.
• W2947745790 hasAuthorship W2947745790A5006135689 @default.
• W2947745790 hasAuthorship W2947745790A5010404968 @default.
• W2947745790 hasAuthorship W2947745790A5018535039 @default.
• W2947745790 hasAuthorship W2947745790A5020294749 @default.
• W2947745790 hasAuthorship W2947745790A5021816409 @default.
• W2947745790 hasAuthorship W2947745790A5023172730 @default.
• W2947745790 hasAuthorship W2947745790A5023237476 @default.
• W2947745790 hasAuthorship W2947745790A5026178160 @default.
• W2947745790 hasAuthorship W2947745790A5035601931 @default.
• W2947745790 hasAuthorship W2947745790A5044297659 @default.
• W2947745790 hasAuthorship W2947745790A5046992544 @default.
• W2947745790 hasAuthorship W2947745790A5062645991 @default.
• W2947745790 hasAuthorship W2947745790A5066924600 @default.
• W2947745790 hasAuthorship W2947745790A5077526239 @default.
• W2947745790 hasAuthorship W2947745790A5079893085 @default.
• W2947745790 hasAuthorship W2947745790A5080250007 @default.
• W2947745790 hasAuthorship W2947745790A5084452918 @default.
• W2947745790 hasAuthorship W2947745790A5085351803 @default.
• W2947745790 hasConcept C121608353 @default.
• W2947745790 hasConcept C126322002 @default.
• W2947745790 hasConcept C141071460 @default.
• W2947745790 hasConcept C168563851 @default.
• W2947745790 hasConcept C197934379 @default.
• W2947745790 hasConcept C207103383 @default.
• W2947745790 hasConcept C2775965419 @default.
• W2947745790 hasConcept C2776248978 @default.
• W2947745790 hasConcept C2776264508 @default.
• W2947745790 hasConcept C2778019345 @default.
• W2947745790 hasConcept C2778695046 @default.
• W2947745790 hasConcept C2992435398 @default.
• W2947745790 hasConcept C44249647 @default.
• W2947745790 hasConcept C526805850 @default.
• W2947745790 hasConcept C535046627 @default.
• W2947745790 hasConcept C71924100 @default.
• W2947745790 hasConcept C90924648 @default.
• W2947745790 hasConceptScore W2947745790C121608353 @default.
• W2947745790 hasConceptScore W2947745790C126322002 @default.
• W2947745790 hasConceptScore W2947745790C141071460 @default.
• W2947745790 hasConceptScore W2947745790C168563851 @default.
• W2947745790 hasConceptScore W2947745790C197934379 @default.
• W2947745790 hasConceptScore W2947745790C207103383 @default.
• W2947745790 hasConceptScore W2947745790C2775965419 @default.
• W2947745790 hasConceptScore W2947745790C2776248978 @default.
• W2947745790 hasConceptScore W2947745790C2776264508 @default.
• W2947745790 hasConceptScore W2947745790C2778019345 @default.
• W2947745790 hasConceptScore W2947745790C2778695046 @default.
• W2947745790 hasConceptScore W2947745790C2992435398 @default.
• W2947745790 hasConceptScore W2947745790C44249647 @default.
• W2947745790 hasConceptScore W2947745790C526805850 @default.
• W2947745790 hasConceptScore W2947745790C535046627 @default.
• W2947745790 hasConceptScore W2947745790C71924100 @default.
• W2947745790 hasConceptScore W2947745790C90924648 @default.
• W2947745790 hasIssue "15_suppl" @default.
• W2947745790 hasLocation W29477457901 @default.
• W2947745790 hasOpenAccess W2947745790 @default.
• W2947745790 hasPrimaryLocation W29477457901 @default.
• W2947745790 hasRelatedWork W2793936709 @default.
• W2947745790 hasRelatedWork W2806021427 @default.
• W2947745790 hasRelatedWork W2806906789 @default.
• W2947745790 hasRelatedWork W2810553047 @default.
• W2947745790 hasRelatedWork W2979385728 @default.
• W2947745790 hasRelatedWork W3016266178 @default.
• W2947745790 hasRelatedWork W3105390383 @default.

• next